WO2004083235A3 - Tie-2 modulators and methods of use - Google Patents

Tie-2 modulators and methods of use Download PDF

Info

Publication number
WO2004083235A3
WO2004083235A3 PCT/US2004/008579 US2004008579W WO2004083235A3 WO 2004083235 A3 WO2004083235 A3 WO 2004083235A3 US 2004008579 W US2004008579 W US 2004008579W WO 2004083235 A3 WO2004083235 A3 WO 2004083235A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
tie
modulators
modulating
Prior art date
Application number
PCT/US2004/008579
Other languages
French (fr)
Other versions
WO2004083235A2 (en
Inventor
Lynne Canne Bannen
S David Brown
Wei Cheng
Atwood Kim Cheung
Lisa Esther Dalrymple
Sergey Epshteyn
Mohamed Abdulkader Ibrahim
Vasu Jammalamadaka
James William Leahy
Gary Lee Lewis
Morrison B Mac
Larry W Mann
John M Nuss
Robin Tammie Noguchi
Jason Jevious Parks
Brian Hugh Ridgway
Joan C Sangalang
Kevin Luke Schnepp
Xian Shi
Matthew A Williams
Wei Xu
Richard Khoury
Original Assignee
Exelixis Inc
Lynne Canne Bannen
S David Brown
Wei Cheng
Atwood Kim Cheung
Lisa Esther Dalrymple
Sergey Epshteyn
Mohamed Abdulkader Ibrahim
Vasu Jammalamadaka
James William Leahy
Gary Lee Lewis
Morrison B Mac
Larry W Mann
John M Nuss
Robin Tammie Noguchi
Jason Jevious Parks
Brian Hugh Ridgway
Joan C Sangalang
Kevin Luke Schnepp
Xian Shi
Matthew A Williams
Wei Xu
Richard Khoury
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Lynne Canne Bannen, S David Brown, Wei Cheng, Atwood Kim Cheung, Lisa Esther Dalrymple, Sergey Epshteyn, Mohamed Abdulkader Ibrahim, Vasu Jammalamadaka, James William Leahy, Gary Lee Lewis, Morrison B Mac, Larry W Mann, John M Nuss, Robin Tammie Noguchi, Jason Jevious Parks, Brian Hugh Ridgway, Joan C Sangalang, Kevin Luke Schnepp, Xian Shi, Matthew A Williams, Wei Xu, Richard Khoury filed Critical Exelixis Inc
Priority to JP2006507414A priority Critical patent/JP4960085B2/en
Priority to EP04757665A priority patent/EP1608373A4/en
Priority to CA2517291A priority patent/CA2517291C/en
Priority to AU2004221812A priority patent/AU2004221812B2/en
Priority to US10/549,300 priority patent/US8013156B2/en
Publication of WO2004083235A2 publication Critical patent/WO2004083235A2/en
Publication of WO2004083235A3 publication Critical patent/WO2004083235A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
PCT/US2004/008579 2003-03-19 2004-03-19 Tie-2 modulators and methods of use WO2004083235A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006507414A JP4960085B2 (en) 2003-03-19 2004-03-19 TIE-2 modulator and usage
EP04757665A EP1608373A4 (en) 2003-03-19 2004-03-19 Tie-2 modulators and methods of use
CA2517291A CA2517291C (en) 2003-03-19 2004-03-19 Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use
AU2004221812A AU2004221812B2 (en) 2003-03-19 2004-03-19 Tie-2 modulators and methods of use
US10/549,300 US8013156B2 (en) 2003-03-19 2004-03-19 Tie-2 modulators and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45656503P 2003-03-19 2003-03-19
US60/456,565 2003-03-19

Publications (2)

Publication Number Publication Date
WO2004083235A2 WO2004083235A2 (en) 2004-09-30
WO2004083235A3 true WO2004083235A3 (en) 2005-03-03

Family

ID=33030100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/008579 WO2004083235A2 (en) 2003-03-19 2004-03-19 Tie-2 modulators and methods of use

Country Status (6)

Country Link
US (1) US8013156B2 (en)
EP (1) EP1608373A4 (en)
JP (1) JP4960085B2 (en)
AU (1) AU2004221812B2 (en)
CA (1) CA2517291C (en)
WO (1) WO2004083235A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
JP5554496B2 (en) 2005-09-19 2014-07-23 ニューロナセント インコーポレイテッド Methods and compositions for stimulating neurogenesis and for inhibiting neuronal degeneration
AU2013211455B2 (en) * 2005-09-19 2017-12-07 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
CA2664621A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
NZ594594A (en) 2009-01-16 2013-11-29 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US8618111B2 (en) * 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
KR102365952B1 (en) 2013-10-14 2022-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 Selectively substituted quinoline compounds
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
TWI704145B (en) 2015-06-05 2020-09-11 芬蘭商奧利安公司 New pharmaceutical compounds
US20240116892A1 (en) * 2022-08-08 2024-04-11 Ajax Therapeutics, Inc. Heterocyclic amide and urea compounds as jak2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI193974A (en) 1973-07-13 1975-01-14 Merck & Co Inc
DE2428030A1 (en) 1974-06-11 1976-01-02 Merck Sharp & Dohme 4-(3-Amino-2-acyloxypropoxyl)-1,2,5-thiadiazoles - useful as beta-adrenergic blocking agents
EP0096006A3 (en) 1982-05-28 1984-12-19 Ciba-Geigy Ag 3-(ureidocyclohexylamino)-propane-1,2-diol derivatives, process for their preparation, pharmaceutical preparations containing these compounds and their therapeutical use
US4547505A (en) 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
US4994476A (en) 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
IT1191845B (en) * 1986-01-20 1988-03-23 Dompe Farmaceutici Spa PHARMACOLOGICALLY ACTIVE ALCHYLOLS
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
SE8803429D0 (en) * 1988-09-28 1988-09-28 Pharmacia Ab NOVEL PYRIDYL AND PYRIMIDYL DERIVATIVES
DE4134467A1 (en) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K HETEROBIARYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
SE9202265D0 (en) 1992-07-31 1992-07-31 Kabi Pharmacia Ab NOVEL- PYRIDYL AND PYRIMIDYLPIPERAZINE DERIVATIVES
TW279864B (en) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv
US5637592A (en) * 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
US5571811A (en) * 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones
US5639754A (en) * 1994-07-12 1997-06-17 Janssen Pharmaceutica N.V. Urea and thiourea derivatives of azolones
SK282252B6 (en) * 1995-01-11 2001-12-03 Samjin Pharmaceutical Co., Ltd. New piperazine derivatives and pharmaceutical composition containing the same
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
JPH1180119A (en) * 1997-07-15 1999-03-26 Sankyo Co Ltd Piperazine derivative
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000051999A1 (en) 1999-03-03 2000-09-08 American Home Products Corporation New diazole derivatives as serotonergic agents
SE9901884D0 (en) * 1999-05-21 1999-05-21 Pharmacia & Upjohn Ab Novel compounds their use and preparation
AU777276C (en) 1999-05-21 2005-07-07 Biovitrum Ab Novel compounds, their use and preparation
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
KR20030024799A (en) 2000-07-20 2003-03-26 뉴로젠 코포레이션 Capsaicin receptor ligands
DE60205727T2 (en) * 2001-01-23 2006-06-29 Eli Lilly And Co., Indianapolis PIPERAZINE AND PIPERIDINE DERIVATIVES AS AGONISTS OF THE MELANOCORTIN RECEPTOR
CA2436487A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
WO2003004488A1 (en) * 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
MXPA04012393A (en) * 2002-06-12 2005-06-17 Chemocentryx 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders.
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AU2004221812A1 (en) 2004-09-30
EP1608373A4 (en) 2010-09-29
EP1608373A2 (en) 2005-12-28
AU2004221812B2 (en) 2010-02-18
CA2517291A1 (en) 2004-09-30
US20070275952A1 (en) 2007-11-29
JP4960085B2 (en) 2012-06-27
JP2006524682A (en) 2006-11-02
WO2004083235A2 (en) 2004-09-30
US8013156B2 (en) 2011-09-06
CA2517291C (en) 2012-05-08

Similar Documents

Publication Publication Date Title
WO2004092196A3 (en) Tie-2 modulators and methods of use
WO2004091480A3 (en) Tie-2 modulators and methods of use
WO2006033943A3 (en) Pyrazole kinase modulators and methods of use
WO2005020921A3 (en) C-kit modulators and methods of use
WO2005117909A3 (en) Kinase modulators and methods of use
WO2005112932A3 (en) Raf modulators and methods of use
WO2005040355A3 (en) Tao kinase modulators and methods of use
WO2005039506A3 (en) P70s6 kinase modulators and method of use
HK1256476A1 (en) C-met modulators and methods of use
WO2003093297A3 (en) Protein kinase modulators and methods of use
WO2006014325A3 (en) C-met modulators and method of use
ATE543821T1 (en) Ä1H-PYRAZOLOÄ3,4-DÜPYRIMIDINE-4-YLÜ-PIPERIDINE OR PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES
WO2004083235A3 (en) Tie-2 modulators and methods of use
WO2004006846A3 (en) Receptor-type kinase modulators and methods of use
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
MY146548A (en) Certain chemicals entities, compositions, and methods
EA200870048A1 (en) Heteroaryl-PYRROLO [2,3-b] PYRIDINES AND PYRROLO [2,3-b] PYRMIDINES AS A INHIBITOR JANUS-KINASE INHIBITORS
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
UA95244C2 (en) Compounds and methods for kinase modulation, and indications therefor
WO2005034869A3 (en) Compounds and compositions as protein kinase inhibitors
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2007008982A3 (en) Methods and composition for modulating foxo1 activity and insulin signaling
WO2004050681A3 (en) Kinase modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004757665

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2517291

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006507414

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004221812

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004221812

Country of ref document: AU

Date of ref document: 20040319

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004221812

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004757665

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10549300

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10549300

Country of ref document: US